Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)

被引：1

作者：

Spigel, David ^{[1
]}

Pietanza, M. Catherine ^{[2
]}

Bauer, Todd ^{[1
]}

Ready, Neal ^{[3
]}

Morgensztern, Daniel ^{[4
]}

Glisson, Bonnie S. ^{[5
]}

Byers, Lauren Averett ^{[5
]}

Johnson, Melissa ^{[1
]}

Burris, Howard ^{[1
]}

Robert, Francisco ^{[6
]}

Han, Tae ^{[7
]}

Bheddah, Sheila ^{[7
]}

Theiss, Noah ^{[8
]}

Watson, Sky ^{[8
]}

Mathur, Deepan ^{[8
]}

Vennapusa, Bharathi ^{[8
]}

Strickland, Donald ^{[1
]}

Zayed, Hany ^{[7
]}

Dylla, Scott ^{[7
]}

Peng, Stanford ^{[7
]}

Govindan, Ramaswamy ^{[4
]}

Rudin, Charles ^{[9
]}

机构：

[1] Tennessee Oncol PLCC, Sarah Cannon Res Inst, Nashville, TN USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Duke Univ, Med Ctr, Durham, NC USA

[4] Washington Univ, Sch Med, St Louis, MO USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] Abbvie Stemcentrx Llc, San Francisco, CA USA

[8] Roche Diagnost, Tucson, AZ USA

[9] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

clinical trial; Rovalpituzumab tesirine; Delta-like protein 3; SCLC;

D O I：

10.1016/j.jtho.2016.11.252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA05.03

引用

页码：S260 / S261

页数：2

共 48 条

[41] Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Mazieres, J.
Duruisseaux, M.
Curcio, H.
Morizane, C.
Galot, R.
Rottey, S.
Stratmann, J. A.
Ma, Y.
Bouzaggou, M.
Geng, L.
Wermke, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1076 - S1077
[42] Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)
Gray, Jhanelle E.
Heist, Rebecca S.
Starodub, Alexander N.
Camidge, D. Ross
Kio, Ebenezer
Masters, Gregory
Purcell, W. Thomas
Guarino, Michael J.
Misleh, Jamal
Schneider, Charles J.
Schneider, Bryan J.
Ocean, Allyson J.
Johnson, Tirrell
Gandhi, Leena
Kalinsky, Kevin
Govindan, Serengulam V.
Maliakal, Pius
Mudenda, Boyd
Wegener, William A.
Sharkey, Robert M.
Goldenberg, David M.
CANCER RESEARCH, 2017, 77
[43] Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies
Cardnell, Robert J.
Li, Lerong
Sen, Triparna
Bara, Rasha
Tong, Pan
Fujimoto, Junya
Ireland, Abbie S.
Guthrie, Matthew R.
Bheddah, Sheila
Banerjee, Upasana
Kalu, Nene N.
Fan, You-Hong
Dylla, Scott J.
Johnson, Faye M.
Wistuba, Ignacio I.
Oliver, Trudy G.
Heymach, John V.
Glisson, Bonnie S.
Wang, Jing
Byers, Lauren A.
ONCOTARGET, 2017, 8 (43) : 73419 - 73432
[44] Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer
Sands, Jacob M.
Champiat, Stephane
Hummel, Horst-Dieter
Paulson, Kelly G.
Borghaei, Hossein
Alvarez, Jean Bustamante
Carbone, David P.
Carlisle, Jennifer W.
Choudhury, Noura J.
Clarke, Jeffrey M.
Gadgeel, Shirish M.
Izumi, Hiroki
Navarro, Alejandro
Lau, Sally C. M.
Lammers, Philip E.
Huang, Shuang
Hamidi, Ali
Mukherjee, Sujoy
Owonikoko, Taofeek K.
CANCER, 2025, 131 (03)
[45] Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer
Willuda, Joerg
Linden, Lars
Lerchen, Hans-Georg
Kopitz, Charlotte
Stelte-Ludwig, Beatrix
Pena, Carol
Lange, Claudia
Golfier, Sven
Kneip, Christoph
Carrigan, Patricia E.
Mclean, Kirk
Schuhmacher, Joachim
von Ahsen, Oliver
Mueller, Joerg
Dittmer, Frank
Beier, Rudolf
El Sheikh, Sherif
Tebbe, Jan
Leder, Gabriele
Apeler, Heiner
Jautelat, Rolf
Ziegelbauer, Karl
Kreft, Bertolt
MOLECULAR CANCER THERAPEUTICS, 2017, 16 (05) : 893 - 904
[46] Preferential tumor-to-normal tissue biodistribution and single-dose efficacy with ABD147, a DLL3-targeted engineered antibody-based radiotherapeutic, in preclinical small cell lung cancer models
Kulic, Iva
Melese, Etienne S.
Cummins, Emma
Mandel, Alex
Viswas, Raja
Abrams, Michael
Judge, Adam
CANCER RESEARCH, 2024, 84 (06)
[47] ABBV-400, a c-Met protein-targeting antibody-drug conjugate (ADC), in patients (Pts) with advanced EGFR wildtype (WT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): Results from a phase I study
De Miguel, M.
Yamamoto, N.
Raimbourg, J.
Cho, B. C.
Gottfried, M.
Stemmer, S. M.
Goldman, J. W.
Blaney, M. E.
Jennaro, T.
Vasilopoulos, A.
Li, R. R.
Freise, K. J.
Aristide, M. R. Neagu
Morrison-Thiele, G.
Hunter, Z. N.
Burns, M.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2024, 35 : S805 - S806
[48] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study
Zhang, L.
Ma, Y.
Zhao, Y.
Fang, W. F.
Zhao, H.
Huang, Y.
Yang, Y.
Hou, X.
Wen, Z.
Zhang, S.
Wang, J.
Xiao, S.
Wang, H.
Zhu, H.
Olivo, M. S.
Zhu, Y.
ANNALS OF ONCOLOGY, 2023, 34

← 1 2 3 4 5 →